|
Market Closed -
OTC Markets
20:59:44 23/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 11.61 USD | -6.45% |
|
+1.04% | +21.95% |
| 09-11 | BioSyent Inc., Q2 2026 Earnings Call, Aug 20, 2026 | |
| 08-21 | Earnings Flash (RX.V) BioSyent Inc. Reports Q2 Revenue C$19.9M | MT |
| Market Cap | 187M 133M 116M 109M 100M 12.71B 188M 1.32B 510M 6.48B 498M 487M 21.01B | P/E 2026 * |
16.5x | P/E 2027 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise Value | 187M 133M 116M 109M 100M 12.71B 188M 1.32B 510M 6.48B 498M 487M 21.01B | EV / Sales 2026 * |
2.56x | EV / Sales 2027 * | 2.25x |
| Free-Float |
64.08% | Yield 2026 * |
-
| Yield 2027 * | - |
OTC MarketsUSD
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| RX | Delayed | |
OTC Markets
| BIOYF | Delayed |
Last Transcript: BioSyent Inc.
| 1 day | -6.45% | ||
| 1 week | +1.04% | ||
| Current month | +0.96% | ||
| 1 month | +2.20% | ||
| 3 months | +19.00% | ||
| 6 months | +3.29% | ||
| Current year | +21.95% |
| 1 week | 11.24 |  | 12.41 |
| 1 month | 11.21 | | 12.41 |
| Current year | 9 | | 12.41 |
| 1 year | 7.63 | | 12.41 |
| 3 years | 5.65 | | 12.41 |
| 5 years | 4.69 | | 12.41 |
| 10 years | 2.15 | | 12.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 01/05/1999 |
Robert March
DFI | Director of Finance/CFO | - | 10/09/2018 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 01/06/1999 |
Peter Lockhard
BRD | Director/Board Member | 62 | 01/06/2002 |
Stephen Wilton
BRD | Director/Board Member | 65 | 16/01/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.45% | +1.04% | - | - | 141M | |
| -1.64% | +1.16% | +54.09% | +109.07% | 1,043B | |
| -0.01% | +0.71% | +52.44% | +67.71% | 649B | |
| -0.05% | +0.98% | +19.08% | +73.55% | 469B | |
| -0.25% | +0.19% | +36.95% | +45.63% | 355B | |
| +0.98% | +2.91% | +20.59% | +27.91% | 270B | |
| -1.91% | +2.42% | +10.41% | +12.53% | 262B | |
| -1.01% | +7.90% | +41.59% | +51.70% | 222B | |
| -0.85% | +2.50% | +32.32% | +101.80% | 189B | |
| -2.53% | -7.47% | -32.63% | -60.67% | 175B | |
| Average | -0.86% | +1.42% | +26.09% | +47.69% | 403.67B | |
| Weighted average by Cap. | +0.44% | +1.34% | +35.89% | +65.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 73.2M 51.93M 45.58M 42.85M 39.17M 4.97B 73.74M 515M 200M 2.54B 195M 191M 8.22B | 83.2M 59.03M 51.81M 48.7M 44.52M 5.65B 83.82M 585M 227M 2.88B 222M 217M 9.35B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/09/26 | $11.61 | -6.45% | 925 |
| 22/09/26 | $12.41 | +8.86% | 1,908 |
| 21/09/26 | $11.40 | +1.33% | 549 |
| 18/09/26 | $11.25 | -1.32% | 3,188 |
| 17/09/26 | $11.40 | -0.78% | 100 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
16.54CAD
Average target price
18.00CAD
Spread / Average Target
+8.83%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
- BIOYF Stock
Select your edition
All financial news and data tailored to specific country editions
